Summary & Overview
HCPCS J9393: Fulvestrant (Teva) Injection, 25 mg
HCPCS Level II code J9393 designates a 25 mg injection of fulvestrant (Teva), a parenteral anti-estrogen used in oncology care. This code is used to distinguish a specific manufacturer formulation that is noted as not therapeutically equivalent to J9395. Nationally, accurate coding of manufacturer- and formulation-specific biologic and injectable drugs matters for billing clarity, inventory management, and payer coverage determination.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for fulvestrant injections, expected sites of administration, and the implications of formulation-specific HCPCS coding. The publication summarizes payer coverage patterns and benchmarking where available, highlights billing and coding practice considerations tied to non-equivalent product codes, and notes relevant policy or reimbursement updates when applicable.
This summary equips revenue cycle, pharmacy, and oncology clinicians with the facts needed to recognize HCPCS Level II code J9393, understand its clinical use as a 25 mg fulvestrant injection, and identify the payer landscape that commonly affects coverage and claims processing.
Billing Code Overview
HCPCS Level II code J9393 describes an injection of fulvestrant (Teva), 25 mg, identified as a non-therapeutically equivalent formulation to J9395. The service type is drug administration / injectable oncology medication, reflecting a systemic anti-estrogen agent used in oncology practice. The typical site of service is outpatient infusion or physician office injectable administration, including ambulatory infusion centers where parenteral cancer therapies are delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman with estrogen receptor–positive, HER2-negative metastatic or locally advanced breast cancer who has progressed on prior endocrine therapy. The oncology clinic schedules an outpatient infusion visit for administration of intramuscular fulvestrant, J9393 (fulvestrant, 25 mg single-dose vial, specific brand Teva not therapeutically equivalent to J9395).
At the visit the clinician documents diagnosis(es), reviews prior therapies, confirms indication for fulvestrant, obtains informed consent, and assesses for contraindications and potential drug interactions. Nursing verifies identity, reviews allergies, obtains baseline vital signs, and prepares the medication per product labeling. Fulvestrant is administered as a deep intramuscular injection (typically into the gluteal muscle) using appropriate aseptic technique. Observation for immediate adverse reactions follows, and the patient receives scheduling for follow-up doses (per dosing schedule) and documentation of lot number, expiration date, dose, route, site, and any administered ancillary medications (e.g., antiemetics or premedication if clinically indicated).
Typical site of service is an outpatient infusion/injection center or oncology clinic procedure room. The clinical workflow includes medication preparation by pharmacy, verification of billing code J9393, application of the appropriate modifier(s) when indicated, and documentation to support medical necessity for oncology drug benefit coverage and payer adjudication.
Coding Specifications
| Modifier | Description |
|---|